SAB Biotherapeutics Inc (SABS) — Cash Flow-to-Debt Ratio
SAB Biotherapeutics Inc (SABS) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of $-16.78 Million could theoretically repay -1% of its total liabilities ($21.32 Million) in one year. See SAB Biotherapeutics Inc (SABS) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SAB Biotherapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for SAB Biotherapeutics Inc across 7 annual periods. Also explore SABS year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SAB Biotherapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for SAB Biotherapeutics Inc. For market capitalisation and broader financial context, see SAB Biotherapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.10x | $-44.78 Million | $21.32 Million | ▼ -11.6% |
| 2024 | -1.88x | $-34.29 Million | $18.23 Million | ▼ -99.6% |
| 2023 | -0.94x | $-25.12 Million | $26.64 Million | ▲ +20.2% |
| 2022 | -1.18x | $-23.46 Million | $19.85 Million | ▼ -2633.8% |
| 2021 | 0.05x | $1.99 Million | $42.59 Million | ▼ -91.8% |
| 2020 | 0.57x | $10.00 Million | $17.53 Million | ▲ +225.8% |
| 2019 | -0.45x | $-9.21 Million | $20.31 Million | — |